FAM177A1

Summary

FAM177A1 (family with sequence similarity 177 member A1, HGNC:19829) is a protein-coding gene on chromosome 14q13.2, encoding Protein FAM177A1 (Q8N128).

This gene encodes a member of a conserved protein family. Alternative splicing results in multiple transcript variants. This gene is thought to be associated with susceptibility to juvenile idiopathic arthritis.

Source: NCBI Gene 283635 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Mendelian neurodevelopmental disorder (Strong, GenCC) — +1 more curated relationship
• GWAS associations: 10
• Clinical variants (ClinVar): 71 total — 6 pathogenic, 3 likely-pathogenic
• Phenotypes (HPO): 44
• MANE Select transcript: NM_173607

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19829
Approved symbol	FAM177A1
Name	family with sequence similarity 177 member A1
Location	14q13.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000151327
Ensembl biotype	protein_coding
OMIM	619181
Entrez	283635

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 7 protein_coding, 7 nonsense_mediated_decay, 1 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000280987, ENST00000382406, ENST00000553852, ENST00000553901, ENST00000553955, ENST00000554052, ENST00000554794, ENST00000555211, ENST00000555260, ENST00000556858, ENST00000699514, ENST00000699515, ENST00000699516, ENST00000699517, ENST00000871849, ENST00000927548

RefSeq mRNA: 3 — MANE Select: NM_173607 NM_001079519, NM_001289022, NM_173607

CCDS: CCDS41944, CCDS9653

Canonical transcript exons

ENST00000280987 — 5 exons

Exon	Start	End
ENSE00002447228	35053278	35053451
ENSE00003976798	35078927	35079024
ENSE00003976807	35081022	35083378
ENSE00003976808	35077150	35077216
ENSE00003976810	35046272	35046628

Expression profiles

Bgee: expression breadth ubiquitous, 258 present calls, max score 97.87.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 65.4670 / max 698.0613, expressed in 1821 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
139200	27.6695	1819
139199	16.6382	1786
139202	8.1172	1754
139205	5.6516	1528
139203	5.0876	1543
139201	1.4003	944
139204	0.4883	234
139206	0.2697	103
139198	0.1284	54
139197	0.0161	9

Top tissues by expression

260 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	97.87	gold quality
left ventricle myocardium	UBERON:0006566	97.55	gold quality
left testis	UBERON:0004533	97.35	gold quality
right testis	UBERON:0004534	97.29	gold quality
corpus callosum	UBERON:0002336	97.05	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	97.04	gold quality
mucosa of transverse colon	UBERON:0004991	97.00	gold quality
rectum	UBERON:0001052	96.98	gold quality
right lung	UBERON:0002167	96.88	gold quality
spinal cord	UBERON:0002240	96.79	gold quality
transverse colon	UBERON:0001157	96.27	gold quality
upper lobe of left lung	UBERON:0008952	96.20	gold quality
upper lobe of lung	UBERON:0008948	96.15	gold quality
myocardium	UBERON:0002349	96.07	gold quality
cortical plate	UBERON:0005343	96.06	gold quality
right coronary artery	UBERON:0001625	96.04	gold quality
substantia nigra	UBERON:0002038	95.96	gold quality
popliteal artery	UBERON:0002250	95.96	gold quality
tibial artery	UBERON:0007610	95.95	gold quality
ascending aorta	UBERON:0001496	95.92	gold quality
aorta	UBERON:0000947	95.91	gold quality
thoracic aorta	UBERON:0001515	95.91	gold quality
endothelial cell	CL:0000115	95.90	gold quality
islet of Langerhans	UBERON:0000006	95.85	gold quality
heart left ventricle	UBERON:0002084	95.80	gold quality
hypothalamus	UBERON:0001898	95.79	gold quality
lower lobe of lung	UBERON:0008949	95.71	gold quality
descending thoracic aorta	UBERON:0002345	95.70	gold quality
epithelial cell of pancreas	CL:0000083	95.69	gold quality
cardiac ventricle	UBERON:0002082	95.68	gold quality

Single-cell (SCXA)

Detected in 11 experiment(s), a significant marker in 10.

Experiment	Marker?	Max mean expression
E-CURD-120	yes	1033.10
E-MTAB-10287	yes	35.99
E-GEOD-135922	yes	23.46
E-CURD-122	yes	22.22
E-MTAB-6701	yes	20.13
E-CURD-46	yes	19.93
E-ANND-3	yes	19.63
E-CURD-88	yes	16.40
E-HCAD-10	yes	7.73
E-MTAB-6678	yes	5.02
E-MTAB-7606	no	365.31

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

100 targeting FAM177A1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-300	99.92	71.76	2856

Literature-anchored findings (GeneRIF, showing 3)

• Remarkable repression of c14orf24 by miR124a was detected during neurogenesis. (PMID:19663910)
• FAM177A1 Inhibits IL-1beta-Induced Signaling by Impairing TRAF6-Ubc13 Association. (PMID:34799425)
• Loss of function of FAM177A1, a Golgi complex localized protein, causes a novel neurodevelopmental disorder. (PMID:38767059)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	fam177a1	ENSDARG00000079636
danio_rerio	FAM177A1	ENSDARG00000100439
mus_musculus	Fam177a2	ENSMUSG00000094103
mus_musculus	Fam177a	ENSMUSG00000095595
rattus_norvegicus	Fam177a1	ENSRNOG00000064975
drosophila_melanogaster	CG8300	FBGN0029937

Paralogs (1): FAM177B (ENSG00000197520)

Protein

Protein identifiers

Protein FAM177A1 — Q8N128 (reviewed: Q8N128)

All UniProt accessions (9): A0A087X212, A0A1Y8EH40, A0A8V8TNB7, Q8N128, G3V3Z5, G3V583, H0YJC3, H0YJX7, R4GN97

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Golgi apparatus.

Disease relevance. Neurodevelopmental disorder with white matter abnormalities and gait disturbance (NEDWMG) [MIM:621152] An autosomal recessive disorder characterized by macrocephaly, global developmental delay, intellectual disability, seizures, behavioral abnormalities, hypotonia, and gait disturbance. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the FAM177 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8N128-1	1	yes
Q8N128-2	2

RefSeq proteins (3): NP_001072987, NP_001275951, NP_775878* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR028260	FAM177	Family

Pfam: PF14774

UniProt features (13 total): sequence conflict 4, modified residue 3, chain 1, region of interest 1, coiled-coil region 1, compositionally biased region 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N128-F1	64.64	0.01

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 1, 70, 71

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 94 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_UP, GTGCCTT_MIR506, SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_UP, COATES_MACROPHAGE_M1_VS_M2_DN, TGCCTTA_MIR124A, chr14q13, KATSANOU_ELAVL1_TARGETS_UP, STK33_SKM_UP, STK33_UP, FOXN3_TARGET_GENES, SKIL_TARGET_GENES, SNRNP70_TARGET_GENES, SRSF9_TARGET_GENES, ZNF202_TARGET_GENES, ZNF22_TARGET_GENES

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): Golgi apparatus (GO:0005794)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

422 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FAM177A1	KRTAP13-4	Q3LI77	506
FAM177A1	C19orf18	Q8NEA5	447
FAM177A1	MED29	Q9NX70	431
FAM177A1	FAM222B	Q8WU58	430
FAM177A1	DEPDC7	Q96QD5	426
FAM177A1	TCAIM	Q8N3R3	402
FAM177A1	C1GALT1C1L	P0DN25	392
FAM177A1	SSC4D	Q8WTU2	389
FAM177A1	ZNF572	Q7Z3I7	382
FAM177A1	ARL6IP6	Q8N6S5	374
FAM177A1	CLHC1	Q8NHS4	371
FAM177A1	FAM120AOS	Q5T036	370
FAM177A1	WDR93	Q6P2C0	368
FAM177A1	PRORP	O15091	368
FAM177A1	NAA16	Q6N069	359

IntAct

16 interactions, top by confidence:

A	B	Type	Score
FAM177A1	SLC27A2	psi-mi:“MI:0914”(association)	0.530
FAM177A1		psi-mi:“MI:0915”(physical association)	0.370
Rcc1	WDR46	psi-mi:“MI:0914”(association)	0.350
MRPS31		psi-mi:“MI:0914”(association)	0.350
RHOJ	PRKCI	psi-mi:“MI:0914”(association)	0.350
DYRK1A	TEX13D	psi-mi:“MI:0914”(association)	0.350
TMPRSS13	TOR1A	psi-mi:“MI:0914”(association)	0.350
FAM177A1	LORICRIN	psi-mi:“MI:0914”(association)	0.350
SLC44A1	UPK3BL1	psi-mi:“MI:0914”(association)	0.350
SLC44A2	CLGN	psi-mi:“MI:0914”(association)	0.350
SLC44A3	CLGN	psi-mi:“MI:0914”(association)	0.350
STK38L	SH3PXD2B	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (106): FAM177A1 (Affinity Capture-MS), FAM204A (Affinity Capture-MS), SLC27A2 (Affinity Capture-MS), C1orf27 (Affinity Capture-MS), SUGP1 (Affinity Capture-MS), UFSP2 (Affinity Capture-MS), EEF1A2 (Affinity Capture-MS), STEAP3 (Affinity Capture-MS), AAGAB (Affinity Capture-MS), SLC4A1AP (Affinity Capture-MS), FAM207A (Affinity Capture-MS), SAR1B (Affinity Capture-MS), TGS1 (Affinity Capture-MS), ARMCX3 (Affinity Capture-MS), DHX38 (Affinity Capture-MS)

ESM2 similar proteins: A2AFR3, A6QLZ5, O08838, O94888, O95983, P0C6S7, P21580, P49418, P50478, Q05B58, Q08DU8, Q14161, Q14CM0, Q1RMZ1, Q32KN2, Q3KR37, Q3ZK22, Q497H0, Q5E948, Q5RD48, Q5REE1, Q5REY7, Q5RFL7, Q5U2M7, Q5UAK0, Q5ZIA0, Q5ZKA4, Q60769, Q66H91, Q6DC60, Q6ZPY2, Q7TQF7, Q7Z6G8, Q8BIZ1, Q8BR63, Q8BXK4, Q8IW50, Q8N108, Q8N128, Q8R3V6

Diamond homologs: A6PVY3, A6QLZ5, Q8BR63, Q8N128

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

71 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	6
Likely pathogenic	3
Uncertain significance	42
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (9)

Variant ID	HGVS	Classification
1686831	NM_173607.5(FAM177A1):c.366_367dup (p.Trp123fs)	Pathogenic
3775083	FAM177A1, 8-KB DEL	Pathogenic
3775084	FAM177A1, 9.7-KB DEL	Pathogenic
3775085	FAM177A1, EX3DEL	Pathogenic
3775086	NM_173607.5(FAM177A1):c.268G>T (p.Glu90Ter)	Pathogenic
3775087	NM_173607.5(FAM177A1):c.209_210del (p.Ile70fs)	Pathogenic
183348	NM_173607.5(FAM177A1):c.366dup (p.Trp123fs)	Likely pathogenic
870577	NC_000014.9:g.35077780_35087566del	Likely pathogenic
870589	NC_000014.9:g.35044389_35052476del	Likely pathogenic

SpliceAI

2301 predictions. Top by Δscore:

Variant	Effect	Δscore
14:35048726:G:T	donor_gain	1.0000
14:35053277:GATGA:G	acceptor_gain	1.0000
14:35053450:CGG:C	donor_loss	1.0000
14:35053452:G:C	donor_loss	1.0000
14:35053453:T:A	donor_loss	1.0000
14:35078919:A:AG	acceptor_gain	1.0000
14:35078920:T:G	acceptor_gain	1.0000
14:35078924:CAGT:C	acceptor_loss	1.0000
14:35078925:A:AG	acceptor_gain	1.0000
14:35078925:AGT:A	acceptor_gain	1.0000
14:35078925:AGTGT:A	acceptor_gain	1.0000
14:35078926:G:GT	acceptor_gain	1.0000
14:35078926:GT:G	acceptor_gain	1.0000
14:35078926:GTG:G	acceptor_gain	1.0000
14:35078926:GTGT:G	acceptor_gain	1.0000
14:35078926:GTGTG:G	acceptor_gain	1.0000
14:35079021:GGAG:G	donor_gain	1.0000
14:35079022:G:GT	donor_gain	1.0000
14:35079022:GAG:G	donor_gain	1.0000
14:35079023:AGGT:A	donor_loss	1.0000
14:35079024:GGTA:G	donor_loss	1.0000
14:35079025:G:GG	donor_gain	1.0000
14:35079025:GTAT:G	donor_loss	1.0000
14:35081016:TTTTA:T	acceptor_loss	1.0000
14:35081017:TTTAG:T	acceptor_loss	1.0000
14:35081019:TAGG:T	acceptor_loss	1.0000
14:35081020:A:AG	acceptor_gain	1.0000
14:35081021:G:GT	acceptor_gain	1.0000
14:35081021:GGAA:G	acceptor_gain	1.0000
14:35085774:TCATC:T	acceptor_gain	1.0000

AlphaMissense

1557 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:35077199:C:A	A107D	1.000
14:35053359:T:C	F60L	0.999
14:35053361:T:A	F60L	0.999
14:35053361:T:G	F60L	0.999
14:35077198:G:C	A107P	0.999
14:35078929:T:C	C114R	0.999
14:35078941:G:A	G118R	0.999
14:35078941:G:C	G118R	0.999
14:35078942:G:A	G118E	0.999
14:35078982:G:C	K131N	0.999
14:35078982:G:T	K131N	0.999
14:35078983:T:C	Y132H	0.999
14:35078993:C:A	A135D	0.999
14:35079011:G:C	R141P	0.999
14:35053360:T:C	F60S	0.998
14:35077162:T:A	W95R	0.998
14:35077162:T:C	W95R	0.998
14:35077196:C:A	A106D	0.998
14:35078930:G:A	C114Y	0.998
14:35078983:T:G	Y132D	0.998
14:35078984:A:C	Y132S	0.998
14:35078984:A:G	Y132C	0.998
14:35078996:T:A	I136N	0.998
14:35053354:T:G	I58S	0.997
14:35053369:G:T	G63V	0.997
14:35053389:A:C	S70R	0.997
14:35053391:C:A	S70R	0.997
14:35053391:C:G	S70R	0.997
14:35078933:A:C	D115A	0.997
14:35078939:T:C	L117P	0.997

dbSNP variants (sampled 300 via entrez): RS1000023907 (14:35044751 G>A), RS1000071847 (14:35077725 A>C,G), RS1000092159 (14:35061064 G>A,C), RS1000157214 (14:35043161 C>T), RS1000173638 (14:35067776 T>A,G), RS1000194474 (14:35059760 G>T), RS1000286709 (14:35048842 G>A), RS1000352768 (14:35073306 G>A), RS1000444491 (14:35049031 C>G,T), RS1000509571 (14:35044423 C>G,T), RS1000614270 (14:35050154 G>A,C), RS1000678965 (14:35061500 A>G,T), RS1000725771 (14:35073747 C>G), RS1000861402 (14:35056504 T>A,G), RS1000918960 (14:35067407 C>T)

Disease associations

OMIM: gene MIM:619181 | disease phenotypes: MIM:621152

GenCC curated gene-disease

Disease	Classification	Inheritance
Mendelian neurodevelopmental disorder	Strong	Autosomal recessive
complex neurodevelopmental disorder	Moderate	Autosomal recessive

Mondo (4): intellectual disability (MONDO:0001071), neurodevelopmental disorder with white matter abnormalities and gait disturbance (MONDO:0976264), complex neurodevelopmental disorder (MONDO:0100038), Mendelian neurodevelopmental disorder (MONDO:0100500)

Orphanet (1): NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

44 total (30 of 44 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000256	Macrocephaly
HP:0000268	Dolichocephaly
HP:0000490	Deeply set eye
HP:0000519	Developmental cataract
HP:0000540	Hypermetropia
HP:0000565	Esotropia
HP:0000582	Upslanted palpebral fissure
HP:0000646	Amblyopia
HP:0000712	Emotional lability
HP:0000718	Aggressive behavior
HP:0000729	Autistic behavior
HP:0000737	Irritability
HP:0000739	Anxiety
HP:0000744	Low frustration tolerance
HP:0000750	Delayed speech and language development
HP:0000752	Hyperactivity
HP:0000954	Single transverse palmar crease
HP:0001249	Intellectual disability
HP:0001250	Seizure
HP:0001257	Spasticity
HP:0001263	Global developmental delay
HP:0001288	Gait disturbance
HP:0001290	Generalized hypotonia
HP:0001347	Hyperreflexia
HP:0001631	Atrial septal defect
HP:0001763	Pes planus
HP:0001864	Clinodactyly of the 5th toe
HP:0001999	Abnormal facial shape
HP:0002007	Frontal bossing

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST004609_210	Monocyte percentage of white cells	1.000000e-10
GCST004627_152	Lymphocyte count	8.000000e-13
GCST005081_8	Bipolar disorder lithium response (continuous) or schizophrenia	2.000000e-08
GCST005856_1	Colorectal carcinoma in primary sclerosing cholangitis	7.000000e-07
GCST006491_3	Circulating fibroblast growth factor 23 levels	5.000000e-06
GCST006585_1903	Blood protein levels	2.000000e-83
GCST90002388_131	Lymphocyte count	9.000000e-21
GCST90002394_480	Monocyte percentage of white cells	1.000000e-19
GCST90002399_354	Neutrophil percentage of white cells	1.000000e-13
GCST90020026_231	Hip index	5.000000e-09

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0007989	monocyte percentage of leukocytes
EFO:0004587	lymphocyte count
EFO:0007990	neutrophil percentage of leukocytes
EFO:0008039	BMI-adjusted hip circumference

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs79403677	Efficacy	3	lithium	Bipolar Disorder

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs79403677	FAM177A1	3	0.00	1	lithium

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases expression, decreases methylation	3
sodium arsenite	decreases expression, increases abundance, increases expression	2
Valproic Acid	increases expression, affects expression	2
FR900359	increases phosphorylation	1
triphenyl phosphate	affects expression	1
beta-lapachone	increases expression	1
butyraldehyde	increases expression	1
potassium chromate(VI)	decreases expression	1
coumarin	increases phosphorylation	1
di-n-butylphosphoric acid	affects expression	1
chloropicrin	affects expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	decreases expression, increases abundance	1
Caffeine	increases phosphorylation	1
Diethylhexyl Phthalate	decreases expression	1
Ivermectin	decreases expression	1
Methyl Methanesulfonate	increases expression	1
Quercetin	decreases expression	1
Rotenone	increases expression	1
Tobacco Smoke Pollution	affects expression	1
Cadmium Chloride	increases expression	1
Copper Sulfate	increases expression	1
Particulate Matter	decreases expression, increases abundance	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E1HS	HeLa M FAM177A1-KO	Cancer cell line	Female
CVCL_E1HT	HeLa M FAM117A1/VPS13B-DKO	Cancer cell line	Female

Clinical trials (associated diseases)

199 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT06310681	Not specified	COMPLETED	Pilot Testing of a Co-adapted Group Programme for Parents/Carers of Children With Complex Neurodisability
NCT07303049	Not specified	NOT_YET_RECRUITING	Cognitive Benefit of Intensive Rehabilitation Using Rhythmic Music Training in Children With Complex Neurodevelopmental Disorder
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02451761	Not specified	COMPLETED	Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
NCT02461420	Not specified	ACTIVE_NOT_RECRUITING	Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
NCT02461459	Not specified	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
NCT02486081	Not specified	COMPLETED	Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population
NCT02504502	Not specified	COMPLETED	Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
NCT02513277	Not specified	COMPLETED	Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study
NCT02561754	Not specified	COMPLETED	Weight Management for Adolescents With IDD
NCT02591446	Not specified	COMPLETED	Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders
NCT02714868	Not specified	COMPLETED	Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)
NCT02721394	Not specified	UNKNOWN	FCT With Young Children With ID in the UK: A Feasibility Project V.1